<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01383499</url>
  </required_header>
  <id_info>
    <org_study_id>205.425</org_study_id>
    <secondary_id>2010-022458-18</secondary_id>
    <nct_id>NCT01383499</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate Asthma</brief_title>
  <official_title>A Phase II Randomised, Double-blind, Placebo-controlled Incomplete Crossover Trial With 4-week Treatment Periods to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (Doses of 1.25 µg, 2.5 µg and 5 µg) Delivered Via Respimat® Inhaler Once Daily in the Evening in Children 6 to 11 Yrs Old With Moderate Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of this trial is to select an optimum dose may be selected based on bronchodilator
      efficacy, safety evaluations and pharmacokinetics of tiotropium bromide.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume (FEV1) Peak (0-3h) Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The FEV1 peak (0-3h) response is determined at the end of the 4 week treatment period. This is the difference between the maximum FEV1 measured within the first 3 hours post dosing and the FEV1 baseline measurement. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The trough FEV1 is defined as the pre-dose FEV1 measured just prior to the last administration of randomised treatment. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) Peak (0-3h) Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The FVC peak (0-3h) response is determined at the end of the 4 week treatment period. This is the difference between the maximum FVC measured within the first 3 hours post dosing and the FVC baseline measurement. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Trough Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The trough FVC response is defined as the pre-dose FVC measured just prior to the last administration of randomised treatment. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Area Under the Curve From 0 to 3 h (AUC0-3h) Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>FEV1 (AUC0-3h) will be calculated as the area under the curve from 0 to 3 hours using the trapezoidal rule divided by the observation time (3 hours) to report in litres. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Area Under the Curve From 0 to 3 h (AUC0-3h) Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>FVC (AUC0-3h) will be calculated as the area under the curve from 0 to 3 hours using the trapezoidal rule divided by the observation time (3 hours) to report in litres. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Morning Peak Expiratory Flow (PEF) Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Mean morning PEF assessed by patients at home. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Evening PEF Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Mean Evening PEF assessed by patients at home. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Number of Puffs of Rescue Medication Per Period (24 h, Daytime and Night-time Use)</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Mean number of inhalations (puffs) of unscheduled rescue salbutamol therapy during whole day (24 h, daytime and night-time use). Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control of Asthma as Assessed by Asthma Control Questionnaire (ACQ)</measure>
    <time_frame>4 weeks</time_frame>
    <description>ACQ is a questionnaire consisting of seven point Likert scale ranging from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The scale describes the frequency and severity of asthma symptoms. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Nighttime Awakenings</measure>
    <time_frame>Baseline and last week of treatment (week 4)</time_frame>
    <description>Mean number of nighttime awakenings due to asthma symptoms as assessed by patients eDiary incorporated in the AM3® device. Analysis adjusted for treatment, period, patient and baseline using a mixed model. The scores for this question used the following scale where: 1='Did not wake up', 2='Woke up once', 3='Woke up 2-5 times', 4='Woke up more than 5 times' and 5='Was awake all night'.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients inhale 2 puffs (low dose) once daily in the evening via Respimat inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients inhale 2 puffs (medium dose) once daily in the evening via Respimat inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients inhale 2 puffs (high dose) once daily in the evening via Respimat inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients inhale 2 puffs of placebo inhalation solution matching tiotropium once daily in the evening via Respimat inhaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium bromide</intervention_name>
    <description>inhalation solution administered via Respimat in 3 different doses</description>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium bromide</intervention_name>
    <description>inhalation solution administered via Respimat in 3 different doses</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium bromide</intervention_name>
    <description>inhalation solution administered via Respimat in 3 different doses</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium bromide</intervention_name>
    <description>inhalation solution administered via Respimat in 3 different doses</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Patients must meet all of the following inclusion criteria to be eligible for enrollment
        into this study:

          1. All patients' parents (or legally accepted caregivers) must sign and date an informed
             consent prior to any study procedures including medication washout and restrictions.
             In addition, an informed assent suitable for this age group has to be obtained from
             patients.

          2. Male or female patients between 6 and 11 years of age (up to 1 day prior to their 12th
             birthday at Visit 1).

          3. All patients must have at least a 6-month history of asthma at the time of enrolment
             into the trial.

          4. All patients must have been on maintenance treatment with inhaled corticosteroids at a
             stable medium dose - a patient is eligible on =200 µg to =400 µg Budesonide DPI or
             equivalent.

          5. All patients must be symptomatic (partly controlled) at Visit 1 (screening) and prior
             to randomisation at Visit 2 as defined by an ACQ mean score of =1.5.

          6. All patients must have a pre-bronchodilator FEV1 =60% and =90% of predicted normal at
             Visit 1. Variation of absolute FEV1 values of Visit 2 (pre-dose) as compared to values
             at Visit 2 (pre-bronchodilator) must be within ± 30%.

          7. All patients must demonstrate an increase in FEV1 of =12% 15 to 30 min. after 200 µg
             salbutamol (albuterol) at Visit 1.

          8. Patients must be able to inhale from the Respimat® inhaler correctly.

          9. Patients must be able to perform all trial related procedures including technically
             acceptable spirometric manoeuvres according to current ATS/ERS standards and the use
             of the electronic diary/peak flow meter.

        Exclusion criteria:

        Patients with any of the following characteristics will not be eligible for entry into this
        study:

          1. Patients with a significant disease other than asthma.

          2. Patients with clinically relevant abnormal screening haematology or blood chemistry
             will be excluded if the abnormality defines a significant disease as defined in
             exclusion criterion 1. For participation in PK sampling, a haemoglobin of less than
             11.3 g/dL will be regarded as exclusion criterion.

          3. Patients with a history of congenital or acquired heart disease, or patients who have
             been hospitalised for cardiac syncope or failure during the past year.

          4. Patients with any unstable or life-threatening cardiac arrhythmia, including cardiac
             arrhythmia requiring intervention (e.g. pacemaker implantation, catheter ablation
             etc.) or a change in drug therapy within the past year.

          5. Patients with a malignancy for which the patient has undergone resection, radiation
             therapy or chemotherapy within the last five years.

          6. Patients with clinically significant lung diseases other than asthma, such as CF, or
             bronchopulmonary dysplasia.

          7. Patients with known active tuberculosis.

          8. Patients who have undergone thoracotomy with pulmonary resection. Patients with a
             history of thoracotomy for other reasons should be evaluated as per exclusion
             criterion No. 1.

          9. Patients who are currently in a pulmonary rehabilitation program or have completed a
             pulmonary rehabilitation program in the 6 weeks prior to the screening visit (Visit
             1).

         10. Patients with known hypersensitivity to anticholinergic drugs, BAC, EDTA or any other
             components of the tiotropium inhalation solution.

         11. Patients with known narrow-angle glaucoma, or any other disease where anticholinergic
             treatment is contraindicated.

         12. Patients with moderate to severe renal impairment, as defined by a creatinine
             clearance &lt;50 mL/min./1.73 m2 BSA, as tiotropium is a predominantly renally excreted
             drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>205.425.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.36003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.36002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mosdos</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.36004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.37101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baldone</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.37105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Balvi</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.37104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.37106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dubulti</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.37102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.37103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.37004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.37003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taurage</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.37001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.37002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.07003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.07004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.07001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.07002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.38004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.425.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zaporizhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2011</study_first_submitted>
  <study_first_submitted_qc>June 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2011</study_first_posted>
  <results_first_submitted>September 23, 2013</results_first_submitted>
  <results_first_submitted_qc>December 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 30, 2013</results_first_posted>
  <last_update_submitted>March 26, 2015</last_update_submitted>
  <last_update_submitted_qc>March 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tio R5/Placebo/Tio R1.25</title>
          <description>Patients treated with Tiotropium 5 mcg in Period 1, with Placebo in Period 2 and with Tiotropium 1.25 mcg in Period 3. All products were administered once daily (QD) in the evening, delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication. No washouts (off treatment periods) between treatments.</description>
        </group>
        <group group_id="P2">
          <title>Tio R1.25/Tio R5/Tio R2.5</title>
          <description>Patients treated with Tiotropium 1.25 mcg in Period 1, with Tiotropium 5 mcg in Period 2 and with Tiotropium 2.5 mcg in Period 3. All products were administered once daily (QD) in the evening, delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication. No washouts (off treatment periods) between treatments.</description>
        </group>
        <group group_id="P3">
          <title>Placebo/Tio R2.5/Tio R5</title>
          <description>Patients treated with Placebo in Period 1, with Tiotropium 2.5 mcg in Period 2 and with Tiotropium 5 mcg in Period 3. All products were administered once daily (QD) in the evening, delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication. No washouts (off treatment periods) between treatments.</description>
        </group>
        <group group_id="P4">
          <title>Tio R2.5/Tio R1.25/Placebo</title>
          <description>Patients treated with Tiotropium 2.5 mcg in Period 1, with Tiotropium 1.25 mcg in Period 2 and with Placebo in Period 3. All products were administered once daily (QD) in the evening, delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication. No washouts (off treatment periods) between treatments.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3 (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Total number of patients randomised and treated at all in the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Total.</title>
          <description>Total number of patients randomised and treated at all in the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.8" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced expiratory volume in 1s (FEV1)</title>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.640" spread="0.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Forced Expiratory Volume (FEV1) Peak (0-3h) Response</title>
        <description>The FEV1 peak (0-3h) response is determined at the end of the 4 week treatment period. This is the difference between the maximum FEV1 measured within the first 3 hours post dosing and the FEV1 baseline measurement. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>The Full analysis set (FAS) is defined as patients randomised, treated, with baseline data and at least one on-treatment efficacy measurement after 4 weeks on treatment within a period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume (FEV1) Peak (0-3h) Response</title>
          <description>The FEV1 peak (0-3h) response is determined at the end of the 4 week treatment period. This is the difference between the maximum FEV1 measured within the first 3 hours post dosing and the FEV1 baseline measurement. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>The Full analysis set (FAS) is defined as patients randomised, treated, with baseline data and at least one on-treatment efficacy measurement after 4 weeks on treatment within a period.</population>
          <units>Litre</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.185" spread="0.025"/>
                    <measurement group_id="O2" value="0.261" spread="0.026"/>
                    <measurement group_id="O3" value="0.290" spread="0.026"/>
                    <measurement group_id="O4" value="0.272" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Tio R5 minus Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>First step of closed testing procedure, where the active treatments are compared to placebo. If this statistical test significant at the 0.05 alpha level then proceed to comparison of the next lower dose to placebo.</p_value_desc>
            <method>Mixed model repeated measures (MMRM)</method>
            <method_desc>This MMRM model includes treatment, period and baseline as fixed effects, and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.087</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.042</ci_lower_limit>
            <ci_upper_limit>0.132</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Tio R2.5 minus Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>Second step of closed testing procedure. If this statistical test significant at the 0.05 alpha level then proceed to comparison of the next lower dose to placebo.</p_value_desc>
            <method>Mixed model repeated measures (MMRM)</method>
            <method_desc>This MMRM model includes treatment, period and baseline as fixed effects, and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.104</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.059</ci_lower_limit>
            <ci_upper_limit>0.149</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tio R1.25 minus Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>Mixed model repeated measures (MMRM)</method>
            <method_desc>This MMRM model includes treatment, period and baseline as fixed effects, and patient as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.075</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.030</ci_lower_limit>
            <ci_upper_limit>0.120</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Tio R5 minus Tio R1.25</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.012</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.034</ci_lower_limit>
            <ci_upper_limit>0.057</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Tio R5 minus Tio R2.5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.017</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.063</ci_lower_limit>
            <ci_upper_limit>0.028</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Tio R2.5 minus Tio R1.25</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.029</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.016</ci_lower_limit>
            <ci_upper_limit>0.074</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response</title>
        <description>The trough FEV1 is defined as the pre-dose FEV1 measured just prior to the last administration of randomised treatment. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS with at least one on-treatment value.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response</title>
          <description>The trough FEV1 is defined as the pre-dose FEV1 measured just prior to the last administration of randomised treatment. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>FAS with at least one on-treatment value.</population>
          <units>Litre</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.085" spread="0.026"/>
                    <measurement group_id="O2" value="0.160" spread="0.026"/>
                    <measurement group_id="O3" value="0.190" spread="0.026"/>
                    <measurement group_id="O4" value="0.183" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) Peak (0-3h) Response</title>
        <description>The FVC peak (0-3h) response is determined at the end of the 4 week treatment period. This is the difference between the maximum FVC measured within the first 3 hours post dosing and the FVC baseline measurement. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS with at least one on-treatment value.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) Peak (0-3h) Response</title>
          <description>The FVC peak (0-3h) response is determined at the end of the 4 week treatment period. This is the difference between the maximum FVC measured within the first 3 hours post dosing and the FVC baseline measurement. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>FAS with at least one on-treatment value.</population>
          <units>Litre</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.202" spread="0.029"/>
                    <measurement group_id="O2" value="0.208" spread="0.029"/>
                    <measurement group_id="O3" value="0.253" spread="0.029"/>
                    <measurement group_id="O4" value="0.239" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Trough Response</title>
        <description>The trough FVC response is defined as the pre-dose FVC measured just prior to the last administration of randomised treatment. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS with at least one on-treatment value.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Trough Response</title>
          <description>The trough FVC response is defined as the pre-dose FVC measured just prior to the last administration of randomised treatment. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>FAS with at least one on-treatment value.</population>
          <units>Litre</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.060" spread="0.030"/>
                    <measurement group_id="O2" value="0.109" spread="0.030"/>
                    <measurement group_id="O3" value="0.107" spread="0.030"/>
                    <measurement group_id="O4" value="0.113" spread="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Area Under the Curve From 0 to 3 h (AUC0-3h) Response</title>
        <description>FEV1 (AUC0-3h) will be calculated as the area under the curve from 0 to 3 hours using the trapezoidal rule divided by the observation time (3 hours) to report in litres. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS with at least one on-treatment value.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Area Under the Curve From 0 to 3 h (AUC0-3h) Response</title>
          <description>FEV1 (AUC0-3h) will be calculated as the area under the curve from 0 to 3 hours using the trapezoidal rule divided by the observation time (3 hours) to report in litres. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>FAS with at least one on-treatment value.</population>
          <units>Litre</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.110" spread="0.025"/>
                    <measurement group_id="O2" value="0.178" spread="0.025"/>
                    <measurement group_id="O3" value="0.208" spread="0.025"/>
                    <measurement group_id="O4" value="0.201" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Area Under the Curve From 0 to 3 h (AUC0-3h) Response</title>
        <description>FVC (AUC0-3h) will be calculated as the area under the curve from 0 to 3 hours using the trapezoidal rule divided by the observation time (3 hours) to report in litres. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS with at least one on-treatment value.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Area Under the Curve From 0 to 3 h (AUC0-3h) Response</title>
          <description>FVC (AUC0-3h) will be calculated as the area under the curve from 0 to 3 hours using the trapezoidal rule divided by the observation time (3 hours) to report in litres. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>FAS with at least one on-treatment value.</population>
          <units>Litre</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.087" spread="0.027"/>
                    <measurement group_id="O2" value="0.097" spread="0.027"/>
                    <measurement group_id="O3" value="0.134" spread="0.027"/>
                    <measurement group_id="O4" value="0.110" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Morning Peak Expiratory Flow (PEF) Response</title>
        <description>Mean morning PEF assessed by patients at home. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS with at least one on-treatment value. For outcome measures obtained by AM3 device one patient in the &quot;TioR2.5&quot; group had no on-treatment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Morning Peak Expiratory Flow (PEF) Response</title>
          <description>Mean morning PEF assessed by patients at home. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>FAS with at least one on-treatment value. For outcome measures obtained by AM3 device one patient in the &quot;TioR2.5&quot; group had no on-treatment data.</population>
          <units>Litre/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.928" spread="5.103"/>
                    <measurement group_id="O2" value="14.474" spread="5.127"/>
                    <measurement group_id="O3" value="12.045" spread="5.177"/>
                    <measurement group_id="O4" value="15.439" spread="5.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Evening PEF Response</title>
        <description>Mean Evening PEF assessed by patients at home. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS with at least one on-treatment value. For outcome measures obtained by AM3 device one patient in the &quot;TioR2.5&quot; group had no on-treatment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Evening PEF Response</title>
          <description>Mean Evening PEF assessed by patients at home. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>FAS with at least one on-treatment value. For outcome measures obtained by AM3 device one patient in the &quot;TioR2.5&quot; group had no on-treatment data.</population>
          <units>Litre/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.568" spread="5.081"/>
                    <measurement group_id="O2" value="9.910" spread="5.103"/>
                    <measurement group_id="O3" value="6.991" spread="5.150"/>
                    <measurement group_id="O4" value="15.910" spread="5.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Number of Puffs of Rescue Medication Per Period (24 h, Daytime and Night-time Use)</title>
        <description>Mean number of inhalations (puffs) of unscheduled rescue salbutamol therapy during whole day (24 h, daytime and night-time use). Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS with at least one on-treatment value. For outcome measures obtained by AM3 device one patient in the &quot;TioR2.5&quot; group had no on-treatment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Number of Puffs of Rescue Medication Per Period (24 h, Daytime and Night-time Use)</title>
          <description>Mean number of inhalations (puffs) of unscheduled rescue salbutamol therapy during whole day (24 h, daytime and night-time use). Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>FAS with at least one on-treatment value. For outcome measures obtained by AM3 device one patient in the &quot;TioR2.5&quot; group had no on-treatment data.</population>
          <units>Puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.664" spread="0.105"/>
                    <measurement group_id="O2" value="-0.691" spread="0.105"/>
                    <measurement group_id="O3" value="-0.314" spread="0.106"/>
                    <measurement group_id="O4" value="-0.550" spread="0.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daytime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.338" spread="0.061"/>
                    <measurement group_id="O2" value="-0.348" spread="0.062"/>
                    <measurement group_id="O3" value="-0.130" spread="0.062"/>
                    <measurement group_id="O4" value="-0.258" spread="0.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Night-time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.354" spread="0.060"/>
                    <measurement group_id="O2" value="-0.355" spread="0.060"/>
                    <measurement group_id="O3" value="-0.180" spread="0.060"/>
                    <measurement group_id="O4" value="-0.272" spread="0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Control of Asthma as Assessed by Asthma Control Questionnaire (ACQ)</title>
        <description>ACQ is a questionnaire consisting of seven point Likert scale ranging from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The scale describes the frequency and severity of asthma symptoms. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS with at least one on-treatment value.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Control of Asthma as Assessed by Asthma Control Questionnaire (ACQ)</title>
          <description>ACQ is a questionnaire consisting of seven point Likert scale ranging from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The scale describes the frequency and severity of asthma symptoms. Analysis adjusted for treatment, period, patient and baseline using a mixed model.</description>
          <population>FAS with at least one on-treatment value.</population>
          <units>Score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.966" spread="0.066"/>
                    <measurement group_id="O2" value="0.909" spread="0.066"/>
                    <measurement group_id="O3" value="0.846" spread="0.066"/>
                    <measurement group_id="O4" value="0.879" spread="0.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Nighttime Awakenings</title>
        <description>Mean number of nighttime awakenings due to asthma symptoms as assessed by patients eDiary incorporated in the AM3® device. Analysis adjusted for treatment, period, patient and baseline using a mixed model. The scores for this question used the following scale where: 1='Did not wake up', 2='Woke up once', 3='Woke up 2-5 times', 4='Woke up more than 5 times' and 5='Was awake all night'.</description>
        <time_frame>Baseline and last week of treatment (week 4)</time_frame>
        <population>FAS with at least one on-treatment value. For outcome measures obtained by AM3 device one patient in the &quot;TioR2.5&quot; group had no on-treatment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25</title>
            <description>Tiotropium 1.25 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Nighttime Awakenings</title>
          <description>Mean number of nighttime awakenings due to asthma symptoms as assessed by patients eDiary incorporated in the AM3® device. Analysis adjusted for treatment, period, patient and baseline using a mixed model. The scores for this question used the following scale where: 1='Did not wake up', 2='Woke up once', 3='Woke up 2-5 times', 4='Woke up more than 5 times' and 5='Was awake all night'.</description>
          <population>FAS with at least one on-treatment value. For outcome measures obtained by AM3 device one patient in the &quot;TioR2.5&quot; group had no on-treatment data.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.135" spread="0.034"/>
                    <measurement group_id="O2" value="-0.104" spread="0.034"/>
                    <measurement group_id="O3" value="-0.080" spread="0.034"/>
                    <measurement group_id="O4" value="-0.099" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks + 30 days if in last period.</time_frame>
      <desc>All AEs, serious and non-serious, occurring during the course of the clinical trial were collected, documented, and reported to the sponsor by the investigator on the appropriate eCRF or SAE reporting forms.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
        </group>
        <group group_id="E2">
          <title>Tio R1.25</title>
          <description>Tiotropium 1.25 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
        </group>
        <group group_id="E3">
          <title>Tio R2.5</title>
          <description>Tiotropium 2.5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
        </group>
        <group group_id="E4">
          <title>Tio R5</title>
          <description>Tiotropium 5 microgram once daily (QD) in the evening delivered by the Respimat® inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

